These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22548340)

  • 21. Tyrosine phosphorylation-dependent activation of NF-kappa B. Requirement for p56 LCK and ZAP-70 protein tyrosine kinases.
    Livolsi A; Busuttil V; Imbert V; Abraham RT; Peyron JF
    Eur J Biochem; 2001 Mar; 268(5):1508-15. PubMed ID: 11231305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular docking guided 3D-QSAR CoMFA analysis of N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of leukocyte-specific protein tyrosine kinase.
    Awale M; Mohan CG
    J Mol Model; 2008 Oct; 14(10):937-47. PubMed ID: 18626671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck).
    Sabat M; VanRens JC; Laufersweiler MJ; Brugel TA; Maier J; Golebiowski A; De B; Easwaran V; Hsieh LC; Walter RL; Mekel MJ; Evdokimov A; Janusz MJ
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5973-7. PubMed ID: 16997556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of 2-amino-heteroaryl-benzothiazole-6-anilides as potent p56(lck) inhibitors.
    Das J; Moquin RV; Lin J; Liu C; Doweyko AM; DeFex HF; Fang Q; Pang S; Pitt S; Shen DR; Schieven GL; Barrish JC; Wityak J
    Bioorg Med Chem Lett; 2003 Aug; 13(15):2587-90. PubMed ID: 12852972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TCR-induced T cell activation leads to simultaneous phosphorylation at Y505 and Y394 of p56(lck) residues.
    Nyakeriga AM; Garg H; Joshi A
    Cytometry A; 2012 Sep; 81(9):797-805. PubMed ID: 22674786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative structure-activity relationship of flavonoid analogues. 3. Inhibition of p56lck protein tyrosine kinase.
    Oblak M; Randic M; Solmajer T
    J Chem Inf Comput Sci; 2000; 40(4):994-1001. PubMed ID: 10955529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics.
    Bamborough P; Angell RM; Bhamra I; Brown D; Bull J; Christopher JA; Cooper AW; Fazal LH; Giordano I; Hind L; Patel VK; Ranshaw LE; Sims MJ; Skone PA; Smith KJ; Vickerstaff E; Washington M
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4363-8. PubMed ID: 17600705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cutting edge: the CD45 tyrosine phosphatase is an inhibitor of Lck activity in thymocytes.
    D'Oro U; Ashwell JD
    J Immunol; 1999 Feb; 162(4):1879-83. PubMed ID: 9973453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pyrrolo[2,3-d]pyrimidines containing diverse N-7 substituents as potent inhibitors of Lck.
    Calderwood DJ; Johnston DN; Munschauer R; Rafferty P
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1683-6. PubMed ID: 12039590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and SAR of novel imidazoquinoxaline-based Lck inhibitors: improvement of cell potency.
    Chen P; Iwanowicz EJ; Norris D; Gu HH; Lin J; Moquin RV; Das J; Wityak J; Spergel SH; de Fex H; Pang S; Pitt S; Shen DR; Schieven GL; Barrish JC
    Bioorg Med Chem Lett; 2002 Nov; 12(21):3153-6. PubMed ID: 12372522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular design, synthesis, and structure-Activity relationships leading to the potent and selective p56(lck) inhibitor BMS-243117.
    Das J; Lin J; Moquin RV; Shen Z; Spergel SH; Wityak J; Doweyko AM; DeFex HF; Fang Q; Pang S; Pitt S; Shen DR; Schieven GL; Barrish JC
    Bioorg Med Chem Lett; 2003 Jul; 13(13):2145-9. PubMed ID: 12798323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery and initial SAR of imidazoquinoxalines as inhibitors of the Src-family kinase p56(Lck).
    Chen P; Norris D; Iwanowicz EJ; Spergel SH; Lin J; Gu HH; Shen Z; Wityak J; Lin TA; Pang S; De Fex HF; Pitt S; Shen DR; Doweyko AM; Bassolino DA; Roberge JY; Poss MA; Chen BC; Schieven GL; Barrish JC
    Bioorg Med Chem Lett; 2002 May; 12(10):1361-4. PubMed ID: 11992777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of human tyrosine kinase, Lck, in yeast Saccharomyces cerevisiae: growth suppression and strategy for inhibitor screening.
    Koyama M; Saito S; Nakagawa R; Katsuyama I; Hatanaka M; Yamamoto T; Arakawa T; Tokunag M
    Protein Pept Lett; 2006; 13(9):915-20. PubMed ID: 17100647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lck is involved in interleukin-2 induced proliferation but not cell survival in human T cells through a MAP kinase-independent pathway.
    Brockdorff J; Nielsen M; Kaltoft K; Mustelin T; Röpke C; Svejaard A; Geisler C; Odum N
    Eur Cytokine Netw; 2000 Jun; 11(2):225-31. PubMed ID: 10903801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase.
    Goldberg DR; Butz T; Cardozo MG; Eckner RJ; Hammach A; Huang J; Jakes S; Kapadia S; Kashem M; Lukas S; Morwick TM; Panzenbeck M; Patel U; Pav S; Peet GW; Peterson JD; Prokopowicz AS; Snow RJ; Sellati R; Takahashi H; Tan J; Tschantz MA; Wang XJ; Wang Y; Wolak J; Xiong P; Moss N
    J Med Chem; 2003 Apr; 46(8):1337-49. PubMed ID: 12672234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ezrin is a substrate for Lck in T cells.
    Autero M; Heiska L; Rönnstrand L; Vaheri A; Gahmberg CG; Carpén O
    FEBS Lett; 2003 Jan; 535(1-3):82-6. PubMed ID: 12560083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New horizons in drug discovery of lymphocyte-specific protein tyrosine kinase (Lck) inhibitors: a decade review (2011-2021) focussing on structure-activity relationship (SAR) and docking insights.
    Elkamhawy A; Ali EMH; Lee K
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1574-1602. PubMed ID: 34233563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 1-Methoxy-agroclavine from Penicillium sp. WC75209, a novel inhibitor of the Lck tyrosine kinase.
    Padmanabha R; Shu YZ; Cook LS; Veitch JA; Donovan M; Lowe S; Huang S; Pirnik D; Manly SP
    Bioorg Med Chem Lett; 1998 Mar; 8(6):569-74. PubMed ID: 9871562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: synthesis, SAR, and pharmacokinetic properties.
    Martin MW; Newcomb J; Nunes JJ; Bemis JE; McGowan DC; White RD; Buchanan JL; DiMauro EF; Boucher C; Faust T; Hsieh F; Huang X; Lee JH; Schneider S; Turci SM; Zhu X
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2299-304. PubMed ID: 17276681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.